IC
HZNP

Inverness Counsel’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Inverness Counsel’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-12,875
Closed -$255K – 113
2015
Q3 		$255K Sell
12,875
-27,575
-68% -$871K 0.02% 96
2015
Q2 		$1.41M Buy
+40,450
New +$1.23M 0.1% 67

Other funds holding HZNP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LPC
Lone Pine Capital Greenwich, Connecticut $16.4B AUM 99.7% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Inverness Counsel's HZNP Position: Q4 2015 in Review

Inverness Counsel sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2015, closing a stake of 12,875 shares — an estimated $255K sold.

Inverness Counsel first reported a position in HZNP in Q2 2015 and held it in 2 quarters. The position peaked at $1.41M in Q2 2015. 202 funds tracked by Wall St. Rank hold HZNP as of Q4 2015.

  • Inverness Counsel reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2015 after selling out during the quarter.
  • Inverness Counsel sold 12,875 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2015, an estimated $255K.
  • Inverness Counsel first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2015 and held it in 2 quarters.
  • Inverness Counsel's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.41M in Q2 2015.
  • 202 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2015.

Based on Inverness Counsel's 13F filing for Q4 2015, filed 4 Feb 2016.